OneSource Specialty Pharma will manufacture biosimilars for Germany-based Formycon AG at its Bengaluru facility. The collaboration aims to boost global biologics supply, yet the company's stock fell 1.24% in morning trade. Investors are evaluating the long-term impact on revenue as the stock faces an 18% decline over the past year.
OneSource Specialty Pharma Ltd. has entered into a strategic manufacturing agreement with German biosimilar developer Formycon AG. Under this arrangement, OneSource will utilize its biologics manufacturing facility in Bengaluru to provide integrated production services, covering everything from drug substance manufacturing to the final fill-finish stage. The company aims to support Formycon’s product pipeline by leveraging its own established infrastructure for complex drug production.
Formycon, which is headquartered in Munich, currently maintains a portfolio that includes three marketed biosimilars and four additional candidates in various stages of clinical development. The collaboration is part of Formycon's broader 'FYB4Growth' initiative, which focuses on building a scalable and cost-efficient supply chain network to serve international markets. For OneSource, this deal represents an effort to utilize its existing capacity by securing high-value international partnerships.
Despite the announcement, market reaction has been muted, with OneSource Specialty Pharma shares trading at ₹1,652.30, down 1.24% around 10:41 AM IST. This movement continues a challenging trend for the stock, which has declined by approximately 8% since the start of 2026 and roughly 18% over the past twelve months. The decline suggests that investors may be prioritizing near-term financial performance and profitability trends over individual project announcements.
From a capacity perspective, OneSource maintains five manufacturing facilities that hold certifications from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These global approvals are essential for the company to act as a contract manufacturer for regulated markets like Europe. However, the business model of contract manufacturing in the biologics sector often involves significant upfront capital costs and long lead times before projects reach full commercial scale.
Investors may monitor several factors following this partnership. Key areas of interest will include the specific timeline for production commencement at the Bengaluru facility, the impact of this contract on operating margins, and how effectively the company can manage costs while scaling up new international orders. Given the competitive nature of the global biosimilar market and the company's recent stock performance, the market will likely track whether this partnership leads to a sustained improvement in cash flow and capacity utilization in the upcoming quarterly results.